GEN-MKT-18-7897-A
Feb 6, 2017 | Blogs, Forensic | 0 comments
As a forensic scientist, what holds you back in the lab? It’s a question we often ask ourselves here at SCIEX, as product development depends on customer wants, needs, satisfaction, and ease of workflow. Ensuring evidence can withstand forensic scrutiny, for example, correlates with the integrity of testing procedures. Knowing this, how do you convince your staff to be confident in results, or convey technical data to a non-technical courtroom audience? If you have been left wondering how to get to the bottom of topics like these, check out the following toxicology toolkit. It’s a bundle of resources at your fingertips that includes a webinar led by Tania A. Saski Ph.D., Northwest Physician Laboratories, Bellevue, Using QTRAP® Technology to Provide Accurate Identification and Confirmation Beyond a Reasonable Doubt, and so much more. Download Info Kit >
Tune in at your convenience to hear about her insights on four forensic cases with questionable results which were rectified using QTRAP® technology. When sample ratios are on the bubble and retention times vary, discover how LC-MS/MS can be a logical solution for difficult confirmations like opiate analysis. Gain higher confidence in your results and make it clear to everyone involved that you have a sample match.
In addition to the webinar, gain access to bundled application notes, a white paper, and in case you missed it, an e-seminar too. Want to get more insight into forensic applications? Visit, Border Security with Accuracy, Reliability, and Reproducibility.
In biopharmaceutical development, sequence variants (SV) are considered an inherent risk of producing complex proteins in living systems. Sequence variants are unintended changes to the amino acid sequence of a biotherapeutic and can be caused by errors in transcription or translation in the host cell, or cell culture and process conditions. Detailed analysis of SVs is important in process and product development to ensure the drug’s safety and efficacy. Even low‑level sequence variants can have significant implications for product quality, safety, and efficacy, making their accurate detection and characterization a critical requirement across development, process optimization, and regulatory submission.
CE‑SDS remains a cornerstone assay for characterizing fragmentation, aggregation, and product‑related impurities in therapeutic proteins. UV detection has been the long‑standing standard. However, it frequently struggles with baseline noise, limited sensitivity for minor fragments, and subjective integration.
At SCIEX, innovation doesn’t stop at instruments; it extends to how you interact with your LC-MS/MS or CE systems every day. That’s why we’re excited to introduce the SCIEX Now spring 2026 improvements: a set of meaningful enhancements shaped directly by your feedback.
Posted by
You must be logged in to post a comment.
Share this post with your network